Fremont, CA (PRWEB) January 17, 2007
Data presented yesterday at the Retina 2007 Meeting in Kauai, Hawaii highlighted the potential benefit of treating wet Age-Related Macular Degeneration (AMD) with the Epi-Rad 90 ™ Ophthalmic System, manufactured by NeoVista, Inc.
Clinical data was presented from 2 separate feasibility studies that utilized the NeoVista product. The first study comprised 2 different doses of radiation (15 Gy and 24 Gy) delivered to the eye. The second study utilized a concomitant approach of 24 Gy radiation plus Avastin™ where one injection of the drug was administered at the time of radiation treatment and one additional injection was administered 30 days later. This is the approach the Company plans to follow when it begins its Pivotal Trial in early 2007. The Company will utilize Lucentis™ instead of Avastin in this trial.
Dr. Eugene de Juan, Jr., the Jean Kelly Stock Professor of Ophthalmology at UCSF and the inventor of the NeoVista treatment approach, commented, "Although the follow-up period is relatively short, the results observed from the Concomitant Trial are extremely encouraging. The percentage of patients who improved in visual acuity by greater than 3 lines was reported at 50%, which is far above the 34% that was reported in the Lucentis MARINA Study. Granted, the NeoVista sample size is much smaller than that garnered from MARINA, but the evidence does support a closer investigation of this Concomitant approach."
"We continue to see vision stability, and in many cases, vision improvement after just one treatment," stated John Hendrick, President and CEO of NeoVista. "The potential impact of our technology will greatly benefit patients, physicians, and the overall health care system. We will soon begin our Pivotal Trial incorporating concomitant use of Lucentis and Epi-Rad 90 therapy. The encouraging results observed in our concomitant feasibility trial have us excited about the future of this approach."
About NeoVista, Inc.
NeoVista, Inc. is a privately held development stage medical device company based in Fremont, CA. The Company intends to enter into a definitive clinical study to support filing for regulatory approval to market the product in the U.S.
For more information, please visit the company website at http://www.neovistainc.com